Aurobindo Pharma Limited has informed the Exchange about merger of a wholly owned stepdown subsidiary with another wholly owned stepdown subsidiary of the Company
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Aurobindo Pharma has informed the stock exchanges that Pharmacin B.V., its wholly owned step-down subsidiary based in the Netherlands, has merged with Agile Pharma B.V., another step-down subsidiary, effective July 1, 2025. Both entities are Dutch companies engaged in manufacturing and marketing of pharmaceutical products. Pharmacin was already a wholly owned subsidiary of Agile, so this merger is an internal consolidation aimed at streamlining operations and saving on regulatory and compliance costs. The combined entity will continue under Agile Pharma B.V. There is no cash consideration, no change in Aurobindo Pharma's shareholding pattern, and no impact on the company's financials on a consolidated basis. Turnover of the two entities for FY25 was Rs. 66.4 million (Agile) and Rs. 197.9 million (Pharmacin).
This is a purely internal restructuring of foreign subsidiaries with no material impact on Aurobindo Pharma's consolidated financials or shareholding. Shareholders are unlikely to see any meaningful effect on the stock price from this announcement.